Improving human health through prevention medicine

“An ounce of prevention is worth a pound of cure.” Scientist, diplomat, and publisher Benjamin Franklin coined this phrase in the 18th century. However, many years later, this insight remains underutilised in modern healthcare.

Patients suffer – often needlessly – while health systems buckle under the weight of avoidable chronic illnesses. Economically, the impact is staggering: Chronic diseases alone cost the EU over €700 billion annually in health care and lost productivity.

The usual suspects, cardiovascular and metabolic diseases, remain the “big killers” that are responsible for the majority of deaths in Europe. Yet many of their risk factors are well understood and modifiable: regular physical activity, a balanced diet, avoiding tobacco, and managing stress can dramatically reduce risk. Doctors are the linchpins of this effort. In private practice, general practitioners are often the first to notice the quiet emergence of long-term risks – rising blood pressure, increasing waistlines, creeping HbA1c levels, or a missing vaccination. Their ability to intervene early, counsel effectively, and refer wisely is vital in curbing disease before it strikes.

In hospitals, physicians not only treat acute manifestations but also provide crucial “teachable moments” for patients – after a heart attack, for instance – to commit to secondary prevention. Then there are more surprising candidates. Take colorectal cancer, a condition with rising incidence across Europe. Regular screening and early detection can reduce mortality by up to 70% – yet participation rates remain uneven, particularly among people from socioeconomically disadvantaged groups. Indeed, health inequalities across the board start early in childhood, making childhood health a prime target for preventative approaches, for example curbing the obesity epidemic.

For diseases like Alzheimer’s and other neurodegenerative conditions, the story of prevention is still unfolding. Only through large cohort studies – involving hundreds of thousands of participants over decades – have researchers identified the web of lifestyle, genetic, and environmental factors at play. Turns out: chronic inflammation, disrupted sleep, and even air pollution can significantly increase the risk of cognitive decline.

In cutting-edge fields like genomics and metabolomics, researchers are making the invisible visible. For example, studies of gene environment interactions show how certain people may be more vulnerable to high-sugar diets based on genetic variants that affect insulin sensitivity. For several conditions, it is even possible to predict onset or complications through genetic risk scores, which can be inexpensively measured at any point in the life course, even at birth. It’s not quite personalised fortune-telling – but we’re getting closer to knowing who might need prevention most, and which kind specifically.

The European Union plays a crucial role in enabling such discoveries. Through programmes like Horizon Europe, the EU has consistently funded high impact research that identifies modifiable risk factors, explores disease mechanisms, and develops population-level strategies. What’s equally important is the EU’s commitment to helping member states integrate these findings into national healthcare systems – ensuring that prevention is a research goal and a healthcare reality. Currently, public research funding is heavily skewed toward developing new treatments. And while that is undoubtedly essential – no one is arguing against new cancer drugs – prevention remains dramatically underfunded.

Yet, the economic logic is clear:

Research suggests that every €1 invested in prevention can yield a return of €14 through avoided healthcare costs and increased productivity.

Imagine what our healthcare systems could do if doctors were not overburdened with preventable conditions. They could spend more time treating diseases that cannot be avoided – those rooted in genetics, external factors, or complex trauma – and deliver better outcomes overall.

Prevention must be a public priority. Governments and public institutions have the mandate to act in the collective long-term interest – through health education, accessible screening programs, clean air initiatives, and healthy urban planning, and the research to guide the way for these interventions.

Prevention research requires robust funding mechanisms, which should be seen as an investment, empowering interdisciplinary collaboration and involving diverse stakeholders including the private sector. And governments must be held accountable for doing so.

Although Benjamin Franklin’s famous quote wasn’t originally about health, he was nonetheless a strong advocate for immunisation against infectious diseases. We would be wise to adopt his intelligent approach when it comes to disease prevention in general – not just in clinical practice, but in research strategies, policy making and the development of digital tools to deliver precision prevention at the population level. Indeed, Helmholtz Health has put together a dedicated Prevention Task Force to develop a roadmap for prevention research and its application globally. Investing in prevention is not just an act of health planning. It is an expression of respect for human potential, a smart economic decision, and a moral imperative in modern medicine. Let’s ensure that future generations don’t just treat preventable diseases – but never suffer them in the first place